BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 32777012)

  • 21. Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy.
    Hay KA
    Br J Haematol; 2018 Nov; 183(3):364-374. PubMed ID: 30407609
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytokine Release Syndrome Grade as a Predictive Marker for Infections in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Treated With Chimeric Antigen Receptor T Cells.
    Park JH; Romero FA; Taur Y; Sadelain M; Brentjens RJ; Hohl TM; Seo SK
    Clin Infect Dis; 2018 Aug; 67(4):533-540. PubMed ID: 29481659
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chimeric antigen receptor T-cell therapy-induced nervous system toxicity: a real-world study based on the FDA Adverse Event Reporting System database.
    Ren X; Zhang G; Li G; Wang Y
    BMC Cancer; 2024 Jan; 24(1):10. PubMed ID: 38166723
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells.
    Karschnia P; Jordan JT; Forst DA; Arrillaga-Romany IC; Batchelor TT; Baehring JM; Clement NF; Gonzalez Castro LN; Herlopian A; Maus MV; Schwaiblmair MH; Soumerai JD; Takvorian RW; Hochberg EP; Barnes JA; Abramson JS; Frigault MJ; Dietrich J
    Blood; 2019 May; 133(20):2212-2221. PubMed ID: 30808634
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Axicabtagene Ciloleucel: Clinical Data for the Use of CAR T-cell Therapy in Relapsed and Refractory Large B-cell Lymphoma.
    Halford Z; Anderson MK; Bennett LL
    Ann Pharmacother; 2021 Mar; 55(3):390-405. PubMed ID: 32698673
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Severe persistent neurotoxicity associated with CAR T therapy in children.
    Andrew EC; Hughes D; Gilsenan M; Mignone C; Khaw SL; Wang SS
    Br J Haematol; 2023 Nov; 203(4):651-655. PubMed ID: 37528536
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Change in Neurocognitive Performance Among Patients with Non-Hodgkin Lymphoma in the First Year after Chimeric Antigen Receptor T Cell Therapy.
    Hoogland AI; Barata A; Logue J; Kommalapati A; Hyland KA; Nelson AM; Eisel SL; Small BJ; James BW; Christy SM; Bulls HW; Booth-Jones M; Jayani RV; Jain MD; Mokhtari S; Chavez JC; Lazaryan A; Shah BD; Locke FL; Jim HSL
    Transplant Cell Ther; 2022 Jun; 28(6):305.e1-305.e9. PubMed ID: 35378330
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development and Use of the Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Axicabtagene Ciloleucel in Large B-Cell Lymphoma: A Review.
    Locke FL; Go WY; Neelapu SS
    JAMA Oncol; 2020 Feb; 6(2):281-290. PubMed ID: 31697310
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Advances in chimeric antigen receptor T cells.
    Beyar-Katz O; Gill S
    Curr Opin Hematol; 2020 Nov; 27(6):368-377. PubMed ID: 32925186
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chimeric antigen receptor T-cell therapy for the treatment of aggressive B-cell non-Hodgkin lymphomas: efficacy, toxicity, and comparative chimeric antigen receptor products.
    Hunter BD; Rogalski M; Jacobson CA
    Expert Opin Biol Ther; 2019 Nov; 19(11):1157-1164. PubMed ID: 31342797
    [No Abstract]   [Full Text] [Related]  

  • 31. Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.
    Zeng C; Cheng J; Li T; Huang J; Li C; Jiang L; Wang J; Chen L; Mao X; Zhu L; Lou Y; Zhou J; Zhou X
    Cytotherapy; 2020 Mar; 22(3):166-171. PubMed ID: 32063474
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy.
    Gauthier J; Turtle CJ
    Curr Res Transl Med; 2018 May; 66(2):50-52. PubMed ID: 29625831
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The incidence of cytokine release syndrome and neurotoxicity of CD19 chimeric antigen receptor-T cell therapy in the patient with acute lymphoblastic leukemia and lymphoma.
    Cao JX; Wang H; Gao WJ; You J; Wu LH; Wang ZX
    Cytotherapy; 2020 Apr; 22(4):214-226. PubMed ID: 32305113
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Toxicity and effectiveness of CD19 CAR T therapy in children with high-burden central nervous system refractory B-ALL.
    Tan Y; Pan J; Deng B; Ling Z; Song W; Xu J; Duan J; Wang Z; Yu X; Chang AH; Feng X
    Cancer Immunol Immunother; 2021 Jul; 70(7):1979-1993. PubMed ID: 33416942
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two with HIV and viral hepatitis.
    Abbasi A; Peeke S; Shah N; Mustafa J; Khatun F; Lombardo A; Abreu M; Elkind R; Fehn K; de Castro A; Wang Y; Derman O; Nelson R; Uehlinger J; Gritsman K; Sica RA; Kornblum N; Mantzaris I; Shastri A; Janakiram M; Goldfinger M; Verma A; Braunschweig I; Bachier-Rodriguez L
    J Hematol Oncol; 2020 Jan; 13(1):1. PubMed ID: 31900191
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The nutritional impact of CD19-targeted CAR-T therapy versus BEAM chemotherapy for adult patients with lymphoma.
    Ahern K; Pham J; Sanderson R; Correia De Farias M; Walsh K
    J Hum Nutr Diet; 2023 Oct; 36(5):2099-2107. PubMed ID: 37489541
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Post-infusion CAR T
    Good Z; Spiegel JY; Sahaf B; Malipatlolla MB; Ehlinger ZJ; Kurra S; Desai MH; Reynolds WD; Wong Lin A; Vandris P; Wu F; Prabhu S; Hamilton MP; Tamaresis JS; Hanson PJ; Patel S; Feldman SA; Frank MJ; Baird JH; Muffly L; Claire GK; Craig J; Kong KA; Wagh D; Coller J; Bendall SC; Tibshirani RJ; Plevritis SK; Miklos DB; Mackall CL
    Nat Med; 2022 Sep; 28(9):1860-1871. PubMed ID: 36097223
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Concise Review of Neurologic Complications Associated with Chimeric Antigen Receptor T-cell Immunotherapy.
    Ruff MW; Siegler EL; Kenderian SS
    Neurol Clin; 2020 Nov; 38(4):953-963. PubMed ID: 33040871
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Toxicity and efficacy of chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma above the age of 70 years compared to younger patients - a matched control multicenter cohort study.
    Ram R; Grisariu S; Shargian-Alon L; Amit O; Bar-On Y; Stepensky P; Yeshurun M; Avni B; Hagin D; Perry C; Gurion R; Sarid N; Herishanu Y; Gold R; Glait-Santar C; Kay S; Avivi I
    Haematologica; 2022 May; 107(5):1111-1118. PubMed ID: 34233446
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma.
    Strati P; Nastoupil LJ; Westin J; Fayad LE; Ahmed S; Fowler NH; Hagemeister FB; Lee HJ; Iyer SP; Nair R; Parmar S; Rodriguez MA; Samaniego F; Steiner RE; Wang M; Pinnix CC; Adkins S; Claussen CM; Martinez CS; Hawkins MC; Johnson NA; Singh P; Mistry HE; Horowitz S; George S; Feng L; Kebriaei P; Shpall EJ; Neelapu SS; Tummala S; Chi TL
    Blood Adv; 2020 Aug; 4(16):3943-3951. PubMed ID: 32822484
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.